Clinical Trial Update: Study of Recombinant Human Endostatin Combined with Temozolomide and Irinotecan in Recurrent Gliomas [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating the combination of recombinant human endostatin with temozolomide and irinotecan for recurrent gliomas is currently recruiti…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma Recurrent
• Lower-grade Glioma Recurrent

Drugs mentioned

• Irinotecan (Irinotecan)
• Recombinant human endostatin (recombinant human endostatin)
• Temozolomide (Temozolomide)

Snippet

Sponsor: Beijing Sanbo Brain Hospital | Conditions: Glioblastoma, Recurrent, Lower Grade Glioma, Recurrent | Phase 2 | Status: RECRUITING